Quick Answer
Vistagen Therapeutics, Inc. reported Total Assets of $84.34 million for the year ending 2025.
- Vistagen Therapeutics, Inc. showed a decrease of -31.8% in Total Assets from 2024 to 2025.
- This data is from Vistagen Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $1.68 million | Q3 2011: $537.3 thousand | Q4 2011: $399.7 thousand | Q1 2012: $881.5 thousand | Q2 2012: $645.0 thousand | Q3 2012: $424.6 thousand | Q4 2012: $326.0 thousand | Q1 2013: $263.7 thousand | Q2 2013: $431.8 thousand | Q3 2013: $406.0 thousand | Q4 2013: $328.9 thousand | Q2 2014: $764.7 thousand | Q3 2014: $386.9 thousand | Q4 2014: $259.4 thousand | Q2 2015: $1.74 million | Q3 2015: $1.93 million | Q4 2015: $2.01 million | Q2 2016: $8.76 million | Q3 2016: $7.02 million | Q4 2016: $5.88 million | Q2 2017: $2.44 million | Q3 2017: $2.62 million | Q4 2017: $14.24 million | Q2 2018: $8.26 million | Q3 2018: $8.89 million | Q4 2018: $7.52 million | Q2 2019: $12.95 million | Q3 2019: $8.74 million | Q4 2019: $5.33 million | Q2 2020: $6.17 million | Q3 2020: $20.27 million | Q4 2020: $109.27 million | Q2 2021: $103.91 million | Q3 2021: $100.50 million | Q4 2021: $90.54 million | Q2 2022: $58.73 million | Q3 2022: $40.70 million | Q4 2022: $29.71 million | Q2 2023: $15.03 million | Q3 2023: $42.20 million | Q4 2023: $131.07 million | Q2 2024: $113.55 million | Q3 2024: $102.50 million | Q4 2024: $92.31 million | Q1 2025: $84.34 million | Q2 2025: $68.92 million | Q3 2025: $80.93 million | Q4 2025: $65.06 million.
- Over the full 15 years of available data (2011 to 2025), Vistagen Therapeutics, Inc.'s Total Assets has grown by 25,963.3%.
- Historical annual values: Fiscal year 2025: $84.34 million | Fiscal year 2024: $123.65 million | Fiscal year 2023: $21.09 million | Fiscal year 2022: $74.64 million | Fiscal year 2021: $108.28 million | Fiscal year 2020: $5.77 million | Fiscal year 2019: $14.01 million | Fiscal year 2018: $11.28 million | Fiscal year 2017: $3.71 million | Fiscal year 2016: $989.8 thousand | Fiscal year 2015: $269.7 thousand | Fiscal year 2014: $263.7 thousand | Fiscal year 2013: $881.5 thousand | Fiscal year 2012: $341.6 thousand | Fiscal year 2011: $323.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: